MedTrace Logo

Safety and Efficacy of NK520 to Treat Relapsed/Refractory Acute Myeloid Leukemia

NCT06541444 · Status: RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2024-08-07

No results posted yet for this study

Summary

This study will evaluate the safety and efficacy of NK520 in the treatment of relapsed/refractory acute myeloid leukemia. NK520 will be administered by intravenous injection. The safety and efficacy of this treatment will be evaluated.

Conditions

  • Relapsed/Refractory Acute Myeloid Leukemia

Interventions

DRUG

NK520

The number of NK520 cell infused for each dosing will be calculated based on body weight of subject. NK520 should be administered through intravenous infusion once a week, for a total of four times.

Sponsors & Collaborators

  • Shanghai Pudong Hospital

    collaborator OTHER

  • Base Therapeutics (Shanghai) Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • zhiguo Long · Shanghai Pudong Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-07-01
Primary Completion
2026-06-01
Completion
2026-06-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06541444 on ClinicalTrials.gov